Moderna reported a Q1 revenue surge to $389 million, up from $108 million a year earlier, driven by international Covid-19 vaccine sales that accounted for $311 million, versus $78 million in U.S. sales. However, the company posted a $1.34 billion loss—nearly double its $971 million pre-year loss—spurred by $900 million in litigation settlement costs after agreeing to pay $950 million to settle patent disputes with Arbutus Biopharma and Genevant Sciences GmbH in March. This marks the first time Moderna has reported a revenue increase since 2022 but signals growing international demand for its vaccines amid waning U.S. demand.